These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25482382)

  • 21. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
    Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O
    Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
    Lee FM; Chan AK; Lau KK; Chan HH
    Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions.
    Ogawa S; Szlam F; Ohnishi T; Molinaro RJ; Hosokawa K; Tanaka KA
    Thromb Haemost; 2011 Dec; 106(6):1215-23. PubMed ID: 22071880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study.
    Körber MK; Langer E; Ziemer S; Perzborn E; Gericke C; Heymann Cv
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):735-40. PubMed ID: 23832064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
    Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
    J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products.
    Tang M; Fenger-Eriksen C; Wierup P; Greisen J; Ingerslev J; Hjortdal V; Sørensen B
    Thromb Res; 2017 Jun; 154():73-79. PubMed ID: 28437748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
    Dickneite G; Dörr B; Kaspereit F; Tanaka KA
    J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
    Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.
    Kwon JO; MacLaren R
    Pharmacotherapy; 2016 Oct; 36(10):1047-1054. PubMed ID: 27547916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass.
    Guzzetta NA; Szlam F; Kiser AS; Fernandez JD; Szlam AD; Leong T; Tanaka KA
    Br J Anaesth; 2014 Feb; 112(2):319-27. PubMed ID: 24193321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
    Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
    Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
    Sørensen B; Ingerslev J
    Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
    Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
    Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes.
    Shaw JR; Carrier M; Dowlatshahi D; Chakraborty S; Tokessy M; Buyukdere H; Castellucci LA
    Thromb Res; 2020 Nov; 195():21-28. PubMed ID: 32645667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
    Hoffman M; Volovyk Z; Monroe DM
    Anesthesiology; 2015 Feb; 122(2):353-62. PubMed ID: 25502064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
    Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
    Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
    Nagakari K; Emmi M; Iba T
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.